Literature DB >> 10206578

Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor.

A Das1, A McLamore, W Song, P G McGuire.   

Abstract

OBJECTIVES: To determine the role of extracellular proteinases in ischemia-induced retinal neovascularization in an animal model and to examine the effect of proteinase inhibitors on retinal neovascularization.
METHODS: Retinal neovascularization was induced in newborn mice exposed to 75% oxygen for 5 days, followed by room air. Retinal extracts underwent zymographic analysis to measure the activity of urokinase and matrix metalloproteinases (MMPs). Some animals under the same conditions also received intraperitoneal injections of an MMP inhibitor. Histological analysis was done to quantitate the neovascular response in these animals.
RESULTS: Levels of urokinase and MMPs (MMP-2 and MMP-9) in retinas were significantly increased in animals with induced retinal neovascularization. Neovascularization was significantly inhibited with intraperitoneal administration of an MMP inhibitor.
CONCLUSION: Systemic inhibition of MMPs may have therapeutic potential in preventing retinopathy associated with retinal neovascularization. CLINICAL RELEVANCE: Because up-regulation and activation of proteinases represents a final common pathway in the process of retinal neovascularization, pharmacological intervention of this pathway may be an alternative therapeutic approach to proliferative retinopathy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10206578     DOI: 10.1001/archopht.117.4.498

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  24 in total

1.  More weapons in the arsenal against ischemic retinopathy.

Authors:  E Keshet
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 2.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

3.  Matrix metalloproteinases (MMP-2 and MMP-9) activity in corneal ulcer and ocular surface disorders determined by gelatin zymography.

Authors:  Arti Singh; O P S Maurya; M V Jagannadhan; Ashok Patel
Journal:  J Ocul Biol Dis Infor       Date:  2012-12-29

4.  Diabetic retinopathy and signaling mechanism for activation of matrix metalloproteinase-9.

Authors:  Ghulam Mohammad; Renu A Kowluru
Journal:  J Cell Physiol       Date:  2012-03       Impact factor: 6.384

5.  The involvement of matrix metalloproteinases 2 and 9 in rat retinal ischemia.

Authors:  Nurit Mathalone; Nitza Lahat; Michal A Rahat; Keren Bahar-Shany; Yoram Oron; Orna Geyer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-06       Impact factor: 3.117

6.  Role of matrix metalloproteinase-9 in the development of diabetic retinopathy and its regulation by H-Ras.

Authors:  Renu A Kowluru
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-10       Impact factor: 4.799

Review 7.  Novel targets against retinal angiogenesis in diabetic retinopathy.

Authors:  Shuang Wang; James K Park; Elia J Duh
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

8.  Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats.

Authors:  Lokesh Kumar Bhatt; Veeranjaneyulu Addepalli
Journal:  Am J Transl Res       Date:  2010-02-12       Impact factor: 4.060

9.  Suppression of retinal neovascularization with an antagonist to vascular endothelial cadherin.

Authors:  Deepti Navaratna; Joann Maestas; Paul G McGuire; Arup Das
Journal:  Arch Ophthalmol       Date:  2008-08

10.  Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis.

Authors:  Masanori Hangai; Norihiko Kitaya; Jingsong Xu; Candy K Chan; Jenny J Kim; Zena Werb; Stephen J Ryan; Peter C Brooks
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.